Binrontin 100 mg/ 300 mg/ 400 mg CAPSULE
PDF Leaflet Revision Date: 26 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Adjunctive treatment for seizure control.
Dosage (summary)
Initial: 300 mg TID; may increase to 900-1800 mg/day.
Special Populations
- Elderly
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; potential risks to fetus.
Key Drug Interactions
- CNS depressants
- Opioids
- Antacids
Contraindications
- Hypersensitivity to gabapentin
- Severe renal impairment
- Children under 12
Common side effects
- Somnolence
- Dizziness
- Ataxia
- Nausea
- Fatigue
Counselling Points
- Monitor for signs of suicidal thoughts
- Avoid abrupt withdrawal
- Use caution with CNS depressants
Serious warnings
- Risk of suicidal ideation
- Severe hypersensitivity reactions
- Respiratory depression
Important Disclaimer
The Binrontin 100 mg/ 300 mg/ 400 mg CAPSULE professional information leaflet below is the property of Aurogen South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
